Replies to post #238900 on Biotech Values

[DewDiligence]

[BGNE]…Positive Topline Results from Phase- 3…Comparing Brukinsa to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

The comparator arm, Rituxan + Treanda, is not exactly the standard of care anymore in first-line CLL. A head-to-head trial against an Imbruvica regimen would’ve been more meaningful, IMO.